Aptevo Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
APVO$1.13-8.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts, unaudited)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Operating expenses: | ||||
| Research and development | $(3,103) | $(3,887) | (10,498) | (13,516) |
| General and administrative | (2,110) | (2,674) | (7,722) | (8,978) |
| Loss from operations | (5,213) | (6,561) | (18,220) | (22,494) |
| Other income: | ||||
| Other income from continuing operations, net | 112 | 227 | 402 | 390 |
| Gain related to sale of non-financial asset | — | — | — | 9,650 |
| Net loss from continuing operations | $(5,101) | $(6,334) | $(17,818) | $(12,454) |
| Discontinued operations: | ||||
| Income from discontinued operations | $— | $— | $— | $946 |
| Net loss | $(5,101) | $(6,334) | $(17,818) | $(11,508) |
| Basic and diluted net loss per share from continuing operations: | ||||
| Basic | $(0.48) | $(22.16) | $(5.01) | $(60.84) |
| Diluted | $(0.48) | $(22.16) | $(5.01) | $(60.84) |
| Basic and diluted net loss per share: | ||||
| Basic | $(0.48) | $(22.16) | $(5.01) | $(56.22) |
| Diluted | $(0.48) | $(22.16) | $(5.01) | $(56.22) |
| Shares used in calculation: | ||||
| Basic | 10,548,470 | 285,886 | 3,554,796 | 204,694 |
| Diluted | 10,548,470 | 285,886 | 3,554,796 | 204,694 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.